Weight Loss and Muscle: Why Body Composition Matters

Three takeaways

1. The published body-composition substudies show preferential fat loss, not a fixed “muscle tax.” In the SURMOUNT-1 DXA substudy, about 75% of the weight lost on tirzepatide was fat, a proportion similar to placebo, and in a STEP 1 analysis the share of body weight made up by lean tissue actually rose [2][3].
2. “Lean mass” is not the same as skeletal muscle. Dual-energy X-ray absorptiometry (DXA) lumps muscle with organs, blood and body water; a professional guideline panel found DXA’s validity for lean mass in clinical populations remains unknown [10]. Muscle-specific and functional measures were not what these trials relied on.
3. The protective levers sit outside the pharmacy. Reviews and national guidance point to muscle-strengthening exercise and adequate, individually assessed nutrition during weight loss — decisions to make with a qualified practitioner, not from an internet number [6][7][8].

Evidence and status panel

Table of contents

1. [Why the scale alone is a blunt instrument](#1)
2. [Weight, fat mass and lean mass](#2)
3. [How lean mass is measured — and why the number is imperfect](#3)
4. [What the medication trials actually measured](#4)
5. [Why the “muscle-loss” panic numbers misread the studies](#5)
6. [What the exercise and nutrition evidence shows](#6)
7. [Questions to bring to a qualified practitioner](#7)

Main article

1. Why the scale alone is a blunt instrument

Body weight is the most available number in health and the least informative per kilogram: it cannot tell lost fat from lost muscle, water or bone mineral — tissues with very different consequences. Dieting always had that problem; GLP-1-based medicines and the triple agonist retatrutide made it urgent, because weekly injections producing twenty-percent weight reductions make the composition of those kilograms the clinically interesting question [1][3][5].

This article defines body composition, reports what the medication trials actually measured, explains why “you’re losing 40% of your muscle” claims misread them, and ends with questions for a qualified practitioner instead of a protocol.

2. Weight, fat mass and lean mass

Three terms do different work. Body weight is everything. Fat mass is triglyceride-rich adipose tissue — the compartment most reliably linked to improvements in blood pressure, blood glucose and inflammation as it shrinks. Lean mass (in DXA-based reporting, “total lean body mass” or, in some older designs, “fat-free mass”) is what remains: skeletal muscle, plus organs, blood, connective tissue and body water [11].

That definition hides the article’s central distinction. Lean mass is a residual, not a muscle measurement. Most of it is not contractile skeletal muscle — and a loss of lean mass does not automatically mean a proportional loss of muscle fibres, let alone of strength. A recent synthesis of incretin-therapy body-composition research makes the same point explicitly: “loss of lean body mass does not necessarily indicate equivalent loss of contractile skeletal muscle or sarcopenia,” and the clinically relevant questions are about strength, physical performance and function [12].

The mirror image matters too: in older age, low muscle mass combined with obesity (“sarcopenic obesity”) is associated with worse function, so starting point changes risk — one more reason a single percentage cannot apply to everyone [9][12].

3. How lean mass is measured — and why the number is imperfect

The medication substudies use dual-energy X-ray absorptiometry, or DXA: two low-energy X-ray beams that partition the body into bone, fat and everything else — a precise, widely used tissue-compartment estimate, not a muscle scan. The “lean” number includes organs, blood and body water, and acute shifts in hydration or glycogen register as lean-tissue change [10][11].

Professional assessment guidance is candid about the limits. ASPEN’s clinical guideline panel — reviewing validity of body composition methods — recommended DXA for assessing fat mass in clinical populations, while noting that “the validity of DXA for lean mass assessment in any clinical population remains unknown,” and that bioelectrical impedance (the technology inside consumer smart scales) and ultrasound lack adequate validity evidence for clinical use [10].

More muscle-specific tools (MRI, CT, ultrasound, tracer methods) exist, and strength or function is testable separately — those belong to a practitioner conversation. What the published substudies used, and what this article reports, are DXA-derived tissue compartments.

4. What the medication trials actually measured

The main incretin trials were powered for body weight and metabolic endpoints — not muscle. The obesity phase 2 retatrutide trial, for example, reported weight change (up to −24.2% at 48 weeks in the highest-dose arm) among its endpoints, with no body-composition endpoint in the main report [5]; the muscle picture came later, from substudies:

Study card — STEP 1 body-composition analysis (semaglutide 2.4 mg, obesity/overweight)
Design: exploratory DXA analysis nested in STEP 1, the 68-week, randomised, placebo-controlled phase 3 trial (1,961 adults randomised) [1][2]. Participants: 140 from 9 sites (95 semaglutide, 45 placebo); mean weight ~98 kg, BMI ~35, 76% female. Intervention: subcutaneous semaglutide 2.4 mg weekly; comparator: placebo plus lifestyle intervention. Endpoint: DXA change from baseline to week 68. Finding: weight −15.0% (placebo −3.6%); total fat mass −19.3%; visceral fat −27.4%; total lean body mass −9.7% — yet the lean share of total body mass increased by 3.0 percentage points [2]. Adverse events: not reported in the DXA analysis; see the parent trial [1]. Funding: parent trial funded by Novo Nordisk. Citation: Wilding et al., Journal of the Endocrine Society 2021;5(Suppl 1) — ENDO 2021 analysis [2].

Study card — SURMOUNT-1 body-composition substudy (tirzepatide, obesity/overweight)
Design: DXA substudy within SURMOUNT-1 (72-week, randomised, placebo-controlled phase 3). Participants: 160 of 2,539 trial participants with DXA at baseline and week 72 (124 tirzepatide, 36 placebo); 73% female, mean weight ~102.5 kg. Intervention: subcutaneous tirzepatide (pooled doses); comparator: placebo. Endpoint: DXA change at week 72. Finding: weight −21.3% (placebo −5.3%); fat mass −33.9% (−8.2%); lean mass −10.9% (−2.6%). “Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo,” with proportions consistent across sex, age and weight-loss subgroups [3]. Adverse events: not reported in the substudy paper; see the parent trial publication. Funding: Eli Lilly (parent programme). Citation: Look et al., Diabetes, Obesity and Metabolism 2025 [3].

Study card — retatrutide body-composition substudy (type 2 diabetes, phase 2)
Design: prespecified DXA substudy of a 36-week, randomised, placebo- and dulaglutide-controlled phase 2 trial in adults with type 2 diabetes [4]. Participants: 189 enrolled; 155 with baseline DXA; 103 completing both scans. Intervention: retatrutide 0.5–12 mg weekly; comparators: dulaglutide 1.5 mg or placebo. Endpoint: percent change in total fat mass at week 36. Finding: fat mass −15.2% (4 mg), −26.1% (8 mg), −23.2% (12 mg) versus −4.5% with placebo; the investigators reported that the proportion of lean-mass loss relative to weight loss “was similar to other obesity treatments” [4]. Adverse events: gastrointestinal events most common; serious events 0–9% by arm; no deaths. Funding: “The study was funded by Eli Lilly and Company.” Citation: Coskun et al., The Lancet Diabetes & Endocrinology 2025 [4]; registry NCT04867785, phase 2 programme [13].

Three honest readings of these cards. First, every published measurement is of tissue compartments, not skeletal muscle itself. Second, the retatrutide data are from a type 2 diabetes population at 36 weeks — a different context from the widely covered 48-week obesity phase 2 results [5], and a reminder that retatrutide remains investigational with no approved product anywhere [14]. Third, the substudy samples are small fractions of the parent trials. And separate trials with different populations and durations cannot rank medicines against each other, as our comparison explainer sets out (article 06).

5. Why the “muscle-loss” panic numbers misread the studies

The viral arithmetic usually runs: “a quarter of the weight lost is lean tissue — you’re losing a quarter of your muscle.” Both halves of that sentence confuse different quantities. The 25% figure (SURMOUNT-1) is the share of the weight lost that was lean tissue; the measured change in lean mass itself was −10.9%, against a total weight change of −21.3% [3]. A share of weight lost is not a percentage of muscle lost — and the trials’ own numbers contradict the panic version: in semaglutide’s DXA analysis, lean body mass share rose by 3.0 percentage points even as its absolute amount fell [2].

Context softens the picture further. The lean/fat proportions reported for tirzepatide were “for both tirzepatide and placebo” [3] — the measured pattern was similar to modest weight loss without the drug. And this predates incretins: in a systematic review of 52 studies in middle-aged and older adults, 81% of diet-only intervention groups lost at least 15% of their body weight as fat-free mass, versus 39% of groups pairing energy restriction with exercise [6]. Weight loss of any kind draws on the lean compartment; the record so far shows no incretin-specific depletion — and no fixed rate at which “your” muscle leaves. Both extremes of the online debate outrun the substudies.

The subtler open question: these studies tracked mass, not strength, power or daily function, and long-term data are limited. The recent synthesis reports available evidence “does not show obvious functional harm,” while stressing the long-term gaps and the need for monitoring in people with lower muscle reserve [12]. “No panic” and “nothing to monitor” are different sentences, and only one is defensible.

6. What the exercise and nutrition evidence shows

None of this makes lean mass irrelevant — it defines where attention is useful. The evidence for preserving it during weight loss is older and mostly consistent: exercise alongside energy restriction preserves fat-free mass far more often than restriction alone [6], which is why national guidance directs adults to muscle-strengthening activity of at least moderate intensity on two or more days a week [7]. That is a guideline, not a programme: the individual dose is a conversation with a qualified exercise professional, especially during rapid weight change.

Nutrition evidence points in the same practical direction without supporting a universal prescription. Guideline groups frame protein needs per kilogram of body weight and adjust them for context: for example, the PROT-AGE position paper recommends 1.0–1.2 g/kg/day for generally healthy older adults, higher ranges in acute or chronic illness, an exception where severe kidney disease is present, and higher intakes for people who are exercising — while finding the evidence insufficient to endorse specific supplement strategies [8]; the ESPEN geriatric guideline takes a similarly situation-specific approach [9]. Applying this to one adult’s age, kidney function, appetite and medication is exactly the question a registered dietitian answers. No universal protein target, shake or “muscle-sparing” formula appears in the credible record.

One edge case: online marketing increasingly offers “muscle-preserving” peptides to people worried about weight-loss drugs. Mitochondrial peptides such as MOTS-c are studied in cells, mice and small human association cohorts — evidence types that cannot establish a clinical muscle-preservation benefit, with unresolved safety flags for their commercial injection forms (article 08) [12][14]. A mechanism is not a demonstrated benefit, and unapproved-compound offers are no substitute for the levers above.

7. Questions to bring to a qualified practitioner

If weight loss — medication-based or otherwise — is on the table for you, these questions are a fair starting agenda for the visit (for medicines, your prescriber; for nutrition, a registered dietitian; for training, a qualified exercise professional):

• What tool would you use to measure my body composition, and how should I interpret changes in lean mass from it?
• What is my baseline for muscle mass and function, and how will we track both?
• What are my nutrition priorities — protein and overall energy — given my health history and kidney function?
• What resistance-training plan suits my current abilities, and how should it progress as my weight changes?
• If a medicine is being considered: which body-composition or functional monitoring would you build into the plan, and at what intervals?
• Which results, if seen, should change the plan — and who reviews them with me?

None of this is individual medical advice; any medicine decision belongs with a qualified practitioner who knows the full picture, including this compound’s jurisdiction-specific status.

Known limitations

• All published body-composition measurements in these trials are DXA-derived tissue compartments, not skeletal muscle mass; ASPEN notes the validity of DXA lean-mass assessment in clinical populations remains unknown, and the trials did not report muscle-specific imaging or function as part of these analyses [3][4][10].
• The substudies are small subsets: 140 (STEP 1, nine sites), 160 (SURMOUNT-1), 155 with baseline DXA (retatrutide type 2 diabetes substudy) [2][3][4].
• Populations and durations differ (64–68-week obesity/overweight trials; a 36-week type 2 diabetes phase 2), so the studies cannot rank medicines against each other [2][3][4][5].
• Muscle strength, physical performance and long-term outcomes were not endpoints of these substudies; available syntheses report no obvious functional harm so far, with long-term data limited [12].
• Both medication substudies’ parent programmes are manufacturer-funded (Novo Nordisk; Eli Lilly), and the retatrutide substudy was funded by Eli Lilly; independent-replication status is limited at this stage [2][3][4].
• Regulatory status statements here are dated 13 October 2026 and US-sourced; South African registration and legal status were not verified for this article.

FAQ

Should I stop or avoid a weight-loss medicine because of “muscle loss” headlines? Decide with your prescriber, not from a headline. The published substudies show preferential fat loss with proportions similar to placebo and to non-drug weight loss, and they did not measure muscle function; they also did not follow outcomes beyond 36–72 weeks [2][3][4].

How much protein do I need during weight loss? There is no universal number, and this article deliberately declines to set one. Protein needs are expressed per kilogram and adjusted for age, activity, illness and kidney health; guideline examples exist for specific populations [8][9], but the individual figure is a question for a registered dietitian.

Are smart scales good enough to track muscle loss? Consumer scales use bioelectrical impedance, whose validity ASPEN’s guideline panel found inadequate for clinical use — hydration shifts alone can move the reading [10]. Clinic-grade tools answer different questions; a practitioner can advise what is appropriate for you.

Do protein powders or “muscle-sparing” peptides protect lean mass? The credible guidance points to adequate, individually assessed nutrition and resistance exercise [6][7][8]. Specific supplement protocols in this context are not established; peptides marketed this way are investigational molecules whose commercial forms lack human efficacy data and carry regulatory safety flags (see article 08).

Sources

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine 2021;384(11):989–1002. PubMed 33567185
2. Wilding J, Batterham R, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study (ENDO 2021). Journal of the Endocrine Society 2021;5(Suppl 1). PMC8089287
3. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism 2025;27(5). doi:10.1111/dom.16275
4. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, randomised trial. The Lancet Diabetes & Endocrinology 2025;13(8). doi:10.1016/S2213-8587(25)00092-000092-0)
5. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine 2023;389(6). doi:10.1056/NEJMoa2301972
6. Weinheimer EM, Sands LP, Campbell WW. A systematic review of the separate and combined effects of energy restriction and exercise on fat-free mass in middle-aged and older adults. Nutrition Reviews 2010;68(7):375–388. PubMed 20591106
7. Physical Activity Guidelines for Americans, 2nd edition — muscle-strengthening guidance (US HHS/ODPHP; checked 13 October 2026).
8. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. JAMDA 2013;14(8):542–559. PubMed 23867520
9. Deutz NEP, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition 2019;38(1):10–47. doi:10.1016/j.clnu.2018.05.024
10. Sheean P, Gonzalez MC, Prado CM, et al. ASPEN Clinical Guidelines: the validity of body composition assessment in clinical populations. JPEN 2020;44(1). doi:10.1002/jpen.1669
11. Prado CMM, Heymsfield SB. Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN 2014;38(8):940–953. PubMed 25239112
12. Kim JY, Kim NH. Beyond fat loss: addressing the sarcopenia challenge of incretin-based therapies. Diabetes & Metabolism Journal 2026;50(5). doi:10.4093/dmj.2026.0702
13. ClinicalTrials.gov — NCT04867785 and NCT04881760, phase 2 retatrutide trials programme (accessed 13 October 2026).
14. Lilly, “What to know about retatrutide” and Lilly Medical, consumer-market availability: investigational; not approved by any regulatory agency; Phase 3 ongoing; BLA submission planned Q1 2027. Checked 13 October 2026. Manufacturer content — attributed as such.

Found an error? Report a correction.

Related articles

• Retatrutide Trial Results: What the Headlines Leave Out — the living trial inventory, including what each study actually measured (article 05).
• Semaglutide, Tirzepatide and Retatrutide: Similarities, Differences and Evidence — why separate trials cannot rank medicines (article 06).
• MOTS-c Explained: Mitochondrial Science and the Human-Evidence Gap — the “muscle-preserving peptide” claims, examined by evidence type (article 08).

Newsletter: The Peptide Science Brief — fortnightly research updates and evidence checks. Sign up at /newsletter/. No personalised medical advice; see medical disclaimer and editorial policy. For the metabolic-health topic hub, see /topics/metabolic-health/.

Suggest a correction